Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain
Respiratory syncytial virus (RSV) is the main cause of low respiratory tract infections in infants under one year of age. In the 2023/2024 season, the monoclonal antibody nirsevimab was available to protect children from RSV, and Spain has become one of the first countries worldwide to implement thi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2365804 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849762891322884096 |
|---|---|
| author | Jaime Jesús Pérez Martín Matilde Zornoza Moreno |
| author_facet | Jaime Jesús Pérez Martín Matilde Zornoza Moreno |
| author_sort | Jaime Jesús Pérez Martín |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) is the main cause of low respiratory tract infections in infants under one year of age. In the 2023/2024 season, the monoclonal antibody nirsevimab was available to protect children from RSV, and Spain has become one of the first countries worldwide to implement this strategy. It is essential to evaluate the results of this first campaign and different characteristics of the immunized population in order to plan next campaigns, especially for countries that are going to include this immunization. Our coverage was high (91.5% for those born during the season and 88.3% globally). For those born during the season, only 4.9% preferred not to immunize at the maternity hospital, which meant an average delay of 27.45 days. We observed a lower coverage in the population of immigrant origin. There was a rapid pace of immunization, since for those born before the beginning of the campaign the mean to be immunized was 15.63 days, without differences between healthy and at-risk children. This allows immunization before the RSV season (90% of the catch-up children had been immunized on November 3). The average age at which all the immunized children have received nirsevimab was lower in healthy children compared to those with risk conditions (49.65 versus 232.85 days). For those born during the campaign, the average age was also lower in healthy children (3.14 versus 14.58 days). In conclusion, we consider that the implementation of the immunization strategy with nirsevimab in the Region of Murcia, Spain, has been a success. |
| format | Article |
| id | doaj-art-bcd3a555ff4a484c8d8e80965f69a4a2 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-bcd3a555ff4a484c8d8e80965f69a4a22025-08-20T03:05:35ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2365804Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in SpainJaime Jesús Pérez Martín0Matilde Zornoza Moreno1Prevention and Health Protection Service, Ministry of Health, Murcia, SpainPrevention and Health Protection Service, Ministry of Health, Murcia, SpainRespiratory syncytial virus (RSV) is the main cause of low respiratory tract infections in infants under one year of age. In the 2023/2024 season, the monoclonal antibody nirsevimab was available to protect children from RSV, and Spain has become one of the first countries worldwide to implement this strategy. It is essential to evaluate the results of this first campaign and different characteristics of the immunized population in order to plan next campaigns, especially for countries that are going to include this immunization. Our coverage was high (91.5% for those born during the season and 88.3% globally). For those born during the season, only 4.9% preferred not to immunize at the maternity hospital, which meant an average delay of 27.45 days. We observed a lower coverage in the population of immigrant origin. There was a rapid pace of immunization, since for those born before the beginning of the campaign the mean to be immunized was 15.63 days, without differences between healthy and at-risk children. This allows immunization before the RSV season (90% of the catch-up children had been immunized on November 3). The average age at which all the immunized children have received nirsevimab was lower in healthy children compared to those with risk conditions (49.65 versus 232.85 days). For those born during the campaign, the average age was also lower in healthy children (3.14 versus 14.58 days). In conclusion, we consider that the implementation of the immunization strategy with nirsevimab in the Region of Murcia, Spain, has been a success.https://www.tandfonline.com/doi/10.1080/21645515.2024.2365804Respiratory syncytial virusnirsevimabpassive immunizationmonoclonal antibodypublic health |
| spellingShingle | Jaime Jesús Pérez Martín Matilde Zornoza Moreno Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain Human Vaccines & Immunotherapeutics Respiratory syncytial virus nirsevimab passive immunization monoclonal antibody public health |
| title | Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain |
| title_full | Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain |
| title_fullStr | Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain |
| title_full_unstemmed | Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain |
| title_short | Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain |
| title_sort | implementation of the first respiratory syncytial rsv immunization campaign with nirsevimab in an autonomous community in spain |
| topic | Respiratory syncytial virus nirsevimab passive immunization monoclonal antibody public health |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2365804 |
| work_keys_str_mv | AT jaimejesusperezmartin implementationofthefirstrespiratorysyncytialrsvimmunizationcampaignwithnirsevimabinanautonomouscommunityinspain AT matildezornozamoreno implementationofthefirstrespiratorysyncytialrsvimmunizationcampaignwithnirsevimabinanautonomouscommunityinspain |